Dianthus Therapeutics Advances Claseprubart into Phase 3 Trial for Myasthenia Gravis — Dianthus Therapeutics, Inc.

Event summary

Dianthus Therapeutics has initiated the Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis (gMG), with top-line results expected in the second half of 2028.
The global, placebo-controlled trial will evaluate claseprubart 300mg/2mL administered subcutaneously every two or four weeks in approximately 195 participants.
Claseprubart demonstrated statistically significant and clinically meaningful improvements over placebo in the Phase 2 MaGic trial, with no drug-related serious adverse events reported.

The big picture

Dianthus Therapeutics is positioning claseprubart as a potential best-in-disease treatment for generalized Myasthenia Gravis, leveraging its selective inhibition of the classical complement pathway. The Phase 3 trial initiation follows promising Phase 2 data and underscores the company's strategy to build a neuromuscular franchise. Success in this trial could validate claseprubart's pipeline-in-a-product potential across multiple autoimmune indications.

What we're watching

Clinical Efficacy: How claseprubart's performance in the Phase 3 trial will compare to its Phase 2 results, particularly in terms of sustained efficacy and safety.
Regulatory Pathway: Whether the Orphan Drug Designation for Myasthenia Gravis will expedite claseprubart's regulatory approval process.
Market Potential: The pace at which Dianthus can expand claseprubart's indications into other autoimmune disorders like Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.